Securities Code: 300003
Securities Abbreviation: Lepu Medical
Announcement No.: 2026-058
Lepu (Beijing) Medical Device Co., Ltd.
Announcement on the Completion of Some Fundraising Projects, Termination of Some Fundraising Projects, and Permanent Supplementation of Related Surplus Raised Funds to Working Capital
The company and all members of the board of directors guarantee the authenticity, accuracy, and completeness of the information disclosed, and that there are no false representations, misleading statements, or material omissions.
Key Information Prompt:
Lepu (Beijing) Medical Device Co., Ltd. (hereinafter referred to as the "Company") publicly issued convertible corporate bonds in March 2021. The sub-projects under the fundraising investment project "Research and Development Project for Innovative Implant-Free Devices for Coronary and Peripheral Intervention" include: "1.3.1 Coronary Small Vessel Drug Balloon, 1.4.1 PTA Drug Balloon Catheter, 1.4.2 Below-Knee Drug Balloon, 1.5.1 Coronary Ultrasound Balloon and Equipment, 1.5.2 Peripheral Ultrasound Balloon and Equipment, 1.6.2 Peripheral Cutting Balloon, 1.7.1 Coronary Imaging Catheter and Equipment." These projects have been approved and launched in China, meeting the conditions for completion. The surplus raised funds amount to 5,268.03 million yuan. The project "1.1.5 New Generation Bioabsorbable Coronary Stent for European and Other Overseas Regions, 1.2 Bioabsorbable Peripheral Stent for European and Other Overseas Regions" has not yet been invested due to strategic adjustments in research and development. The remaining raised funds amount to 35,340 million yuan. The company plans to permanently supplement working capital with a total of 40,608.03 million yuan from the surplus funds of these fundraising projects, to be used for the company's daily production, operation, and business development.
This matter of permanently supplementing working capital with surplus funds from some fundraising projects has been reviewed and approved by the second meeting of the seventh board of directors. The sponsor, Guotai Junan Securities Co., Ltd., has issued a no-objection verification opinion on this matter.
This matter still needs to be submitted for approval by the company's shareholders' meeting.
Lepu (Beijing) Medical Device Co., Ltd. (hereinafter referred to as the "Company") held the second meeting of the seventh board of directors on August 20, 2026, which reviewed and approved the "Proposal on the Completion of Some Fundraising Projects, Termination of Some Fundraising Projects, and Permanent Supplementation of Related Surplus Raised Funds to Working Capital."
In accordance with the "Supervision Regulations for the Management of Raised Funds by Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 2 - Normative Operation of GEM Listed Companies," and other relevant laws, regulations, and normative documents, this proposal still needs to be submitted for approval by the company's shareholders' meeting. The relevant matters are hereby announced as follows:
1